- Home
- NET vs ZTS Comparison
NET vs ZTS Comparison
Compare NET & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NET | ZTS |
|---|---|---|
| Founded | 2009 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.5B | 54.8B |
| IPO Year | 2019 | 2013 |
Fundamental Metrics
Financial Performance| Metric | NET | ZTS |
|---|---|---|
| Price | $172.11 | $127.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 26 | 11 |
| Target Price | ★ $229.38 | $166.60 |
| AVG Volume (30 Days) | ★ 5.0M | 4.6M |
| Earning Date | 02-10-2026 | 02-12-2026 |
| Dividend Yield | N/A | ★ 1.67% |
| EPS Growth | N/A | ★ 11.64 |
| EPS | N/A | ★ 5.94 |
| Revenue | $2,013,376,000.00 | ★ $9,397,000,000.00 |
| Revenue This Year | $29.73 | $3.04 |
| Revenue Next Year | $27.56 | $4.99 |
| P/E Ratio | ★ N/A | $21.35 |
| Revenue Growth | ★ 28.07 | 2.68 |
| 52 Week Low | $89.42 | $115.25 |
| 52 Week High | $260.00 | $177.40 |
Technical Indicators
Market Signals| Indicator | NET | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 38.40 | 61.31 |
| Support Level | $162.01 | $122.21 |
| Resistance Level | $185.22 | $127.66 |
| Average True Range (ATR) | 10.68 | 2.95 |
| MACD | -1.49 | 0.46 |
| Stochastic Oscillator | 5.32 | 97.46 |
Price Performance
Historical ComparisonAbout NET Cloudflare Inc.
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy and execute code without maintaining servers.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its USA business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.